ArticleCurrent microbiology2026
Antimicrobial Potential and Genomic Insights of Novel Klebsiella Phage SBP against K-112 Serotype.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibiofilm efficacy and genomic characterization of a lytic bacteriophage targeting MDR uropathogenic Escherichia coli.Archives of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Klebsiella pneumoniae is an ESKAPE pathogen, it is implicated in various opportunistic infections. This study was aimed to isolate and characterize SBP phage against Klebsiella pneumoniae K-112 serotype. SBP phage was isolated from sewage water and exhibits serotype specific narrow host range. Its burst size is 198 pfu/cell with 25 min of latent period. SBP phage showed excellent growth controlling ability for 8–10 h against planktonic cells. It was able to remove 24 h old biofilm. Host bacterial strains showed lower bacteriophage insensitive mutant frequency against SBP phage corresponding to 2.42 ± 0.49 × 10− 7 at MOI-1. SBP phage demonstrated excellent stability at various conditions of pH and temperature. It has 49 kb double stranded DNA genome with GC content of 48.7%. A total of 78 ORFs were predicted, among them 22 (28%) encoded proteins with known function. SBP phage carries DNA-directed-DNA and RNA polymerase genes. Replication and transcription-related genes, DNA packaging enzymes were annotated in its genome. No lysogeny related genes were identified. It contains p-21 like SAR-endolysin lysis cassette. It was classified as lytic virus of Jedunavirus genus of Caudoviricetes class. It does not contain any bacteria related virulence factors and antibiotic resistance genes, which makes it a suitable candidate for phage therapy.
Indexed as
Identifiers
41931146What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.